GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Cash Flow from Others

Y-Biologics (XKRX:338840) Cash Flow from Others : ₩11,232 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Cash Flow from Others?

Y-Biologics's cash flow from others for the three months ended in Mar. 2024 was ₩-615 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Mar. 2024 was ₩11,232 Mil.


Y-Biologics Cash Flow from Others Historical Data

The historical data trend for Y-Biologics's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Cash Flow from Others Chart

Y-Biologics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Others
Get a 7-Day Free Trial 10,736.85 184.96 2,143.58 -346.83 806.13

Y-Biologics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only 1,511.02 1,379.13 -312.40 10,779.86 -614.51

Y-Biologics Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩11,232 Mil.

Y-Biologics Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Y-Biologics's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Y-Biologics (XKRX:338840) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR
Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines